Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

J. M. McGree, C. Hockham, S. Kotwal, A. Wilcox, A. Bassi, C. Pollock, L. M. Burrell, T. Snelling, V. Jha, M. Jardine, M. Jones, for the CLARITY Trial Steering Committee
doi: https://doi.org/10.1101/2021.08.17.21262196

Article usage

Article usage: August 2021 to November 2024

AbstractFullPdf
Aug 2021820999
Sep 20217755372
Oct 20211131550
Nov 202186422
Dec 20217418
Jan 202247713
Feb 202276164
Mar 202257451
Apr 202255345
May 202229112
Jun 202230111
Jul 20223056
Aug 20224274
Sep 202235410
Oct 20223806
Nov 20223025
Dec 20222618
Jan 202320118
Feb 20231765
Mar 20232505
Apr 20232236
May 20232096
Jun 20231375
Jul 20231312
Aug 202322157
Sep 202322510
Oct 20231745
Nov 202323211
Dec 20231506
Jan 20241114
Feb 20241944
Mar 20241023
Apr 20241079
May 20241102
Jun 20241843
Jul 20241036
Aug 20241125
Sep 20242814
Oct 20241657
Nov 2024714
Back to top
Posted August 22, 2021.
Download PDF
Data/Code
Email
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
J. M. McGree, C. Hockham, S. Kotwal, A. Wilcox, A. Bassi, C. Pollock, L. M. Burrell, T. Snelling, V. Jha, M. Jardine, M. Jones, for the CLARITY Trial Steering Committee
medRxiv 2021.08.17.21262196; doi: https://doi.org/10.1101/2021.08.17.21262196
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area